Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix (NASDAQ:OFIX) said CEO Massimo Calafiore and CFO Julie Andrews will present at two investor conferences in early March 2026: Canaccord Genuity Musculoskeletal Conference on March 2 at 9:30 am CT and TD Cowen Health Care Conference on March 3 at 11:10 am ET.
According to the company, live and archived webcasts will be available in the Events & Presentations section of the Orthofix investor website.
Orthofix (NASDAQ:OFIX) will release fourth quarter and full-year 2025 financial results on February 24, 2026 before market open. A conference call and webcast to review results will be held at 8:30 am Eastern Time the same day.
Dial-in numbers: U.S. (888) 596-4144; international (646) 968-2525; conference ID 2236604. The webcast and a copy of the release will be available at ir.Orthofix.com. Investors are encouraged to consult the Investors section at www.orthofix.com for updates.
Summary not available.
Orthofix (NASDAQ:OFIX) said President & CEO Massimo Calafiore and CFO Julie Andrews will participate in investor conferences in November 2025: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Nov 11, 2025 at 1:15 PM ET; Stifel Healthcare Conference in New York on Nov 12, 2025 at 10:00 AM ET; and Jefferies Global Healthcare Conference in London on Nov 18–19, 2025 for 1x1 meetings.
Investors can access live and archived webcasts in the Events & Presentations section of Orthofix Investor Relations at ir.orthofix.com. The company also posts updates in the Investors section of orthofix.com.
Orthofix (NASDAQ:OFIX) will release third quarter 2025 financial results on Tuesday, November 4, 2025 before market open.
The company will host a conference call and webcast to review results on November 4, 2025 at 8:30 AM Eastern Time. U.S. dial-in is (888) 596-4144; international dial-in is (646) 968-2525; conference ID 5112586. A webcast and the press release will be available at ir.Orthofix.com.
Orthofix notes it posts investor updates in the Investors section of its website and encourages investors to check www.orthofix.com for official information.
Orthofix (NASDAQ:OFIX) reported its Q2 2025 financial results with pro forma net sales of $200.7 million, representing a 4% increase on a constant currency basis year-over-year. The company posted a net loss of $(14.1) million, or $(0.36) per share.
Key highlights include U.S. Spine Fixation growth of 5%, Bone Growth Therapies sales of $62.6 million (up 6%), and Global Orthopedics sales of $33.3 million with 5% constant currency growth. The company achieved its sixth consecutive quarter of adjusted EBITDA margin expansion, with pro forma adjusted EBITDA of $20.6 million and positive free cash flow of $4.5 million.
Orthofix reaffirmed its full-year 2025 guidance, expecting pro forma net sales between $808-816 million and adjusted EBITDA of $82-86 million.
Orthofix Medical (NASDAQ:OFIX), a global medical technology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will deliver a presentation on Wednesday, August 13, 2025, at 9:00 am Eastern Time.
Investors can access both the live and archived versions of the presentation through the "Events & Presentations" section on Orthofix's Investor Relations website at ir.orthofix.com. The company also maintains regular investor updates on its main website at www.orthofix.com.
Orthofix Medical (NASDAQ:OFIX), a global medical technology company, will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The company will host a conference call and webcast at 8:30 AM ET on the same day.
Investors can join the conference call by dialing (888) 596-4144 in the U.S. or (646) 968-2525 internationally, using conference ID 4830464. The webcast and earnings release will be available on the company's investor relations website.
Orthofix Medical Inc. (NASDAQ:OFIX) reported its Q1 2025 financial results with net sales of $193.6 million, representing a 2.7% increase year-over-year. The company posted a net loss of $(53.1) million, or $(1.35) per share. Notable performance includes Bone Growth Therapies sales growth of 5%, Global Orthopedics achieving 11% constant currency growth, and U.S. Spine Fixation growth of 4%.
The company updated its 2025 guidance, now expecting net sales between $808-816 million, while reaffirming non-GAAP adjusted EBITDA guidance of $82-86 million. Pro forma adjusted EBITDA for Q1 was $11.4 million, showing a 200 basis points margin expansion. The company is executing a commercial channel optimization strategy, though this has caused some softness in Biologics and Spine Fixation segments.
Cash position stood at $60.5 million as of March 31, 2025, down from $85.7 million in December 2024, primarily due to annual bonus payments and commissions.